AveXis Company Profile (NASDAQ:AVXS)

Analyst Ratings

Consensus Ratings for AveXis (NASDAQ:AVXS) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $45.00 (17.83% upside)

Analysts' Ratings History for AveXis (NASDAQ:AVXS)
Show:
DateFirmActionRatingPrice TargetActions
7/15/2016Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Jefferies GroupDowngradeBuy -> Hold$39.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Goldman Sachs Group Inc.Boost Price TargetBuy$28.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Chardan CapitalReiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016BMO Capital MarketsInitiated CoverageOutperform$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for AveXis (NASDAQ:AVXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AveXis (NASDAQ:AVXS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AveXis (NASDAQ:AVXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AveXis (NASDAQ:AVXS)
DateHeadline
07/22/16 07:40 PMBigger and better: 2016 IPOs that raised more than $100 million are up over 30%
07/21/16 02:41 PMActive Stocks on Major Advance Today – AVXS, ISRG, OPGN, AWH, CTAS, SPU, BGI
07/20/16 10:45 AMWednesday Sector Leaders: Biotechnology, Drugs
07/20/16 10:45 AMAveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
07/18/16 02:44 PM4 New IPOs This Week Led by Patheon IPO (NYSE: PTHN)
07/11/16 07:13 AMAveXis Appoints Michael B. Johannesen as Senior Vice President, General Counsel and Chief Compliance Officer - [at noodls] - CHICAGO, July 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic ...
06/28/16 08:01 PMCure SMA Releases 2016 Updates from Drug Programs in Clinical Trials
06/27/16 09:03 AMTwilio, other recent IPOs a bright spot among market slump -
06/24/16 04:16 PMAVEXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/23/16 10:28 AMAveXis (NASDAQ:AVXS) price target bumped up to $42 as announced today by Jefferies & Co
06/22/16 02:39 PMJefferies Downgrades AveXis, Cites Valuation
06/10/16 08:33 AMThese 5 Stocks Are Poised for Breakouts -
06/06/16 04:18 PMAveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference - [at noodls] - CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological ...
06/02/16 10:04 AMAveXis (AVXS) is in Overbought Territory: What's Next? -
06/02/16 07:40 AMAveXis (AVXS) Looks Good: Stock Adds 6.5% in Session -
05/23/16 07:06 AMManufacturing Stocks Daily Roundup - Contrafect Common (CFRX)- The company’s stocks surged 11.87 pct. Avexis Inc Cmn Stk (AVXS)- AVXS stock is up 11.33 pct. Genocea Biosciences (GNCA)- The company’s stocks surged 11.39 pct. Flex Pharma Inc. Cm (FLKS)- The company’s shares rose 11.08 pct.
05/16/16 07:32 AMAveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - CHICAGO, May 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological ...
05/13/16 03:29 PMAVEXIS, INC. Files SEC form 10-Q, Quarterly Report -
05/13/16 08:25 AMEdited Transcript of AVXS earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:04 PMAveXis (AVXS) Shares March Higher, Can It Continue? - As of late, it has definitely been a great time to be an investor in AveXis, Inc. AVXS. The stock has moved higher by 55.2% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical ...
05/12/16 03:01 PMAveXis Reports First Quarter 2016 Financial and Operating Results - [GlobeNewswire] - Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1. Conference call May 12 at 4:30 p.m. EDT. CHICAGO, May 12, 2016-- AveXis, Inc., a clinical-stage gene therapy ...
05/12/16 06:44 AMAveXis Inc Earnings Call (Q1 2016) - AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy ...
05/12/16 06:07 AMQ1 2016 AveXis Inc Earnings Release - After Market Close -
05/11/16 09:03 AMDrug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY -
05/11/16 09:03 AMDrug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY -
05/10/16 07:08 AMAveXis (AVXS), Argos (ARGS), Depomed (DEPO) Top Moving Stocks at the Close - AveXis Inc (AVXS) traded at $31.41 + 6.08 (24.00 percent) on 236,111 stock volume. The company is — year to date, and — during the past four quarters. Argos Therapeutics Inc. (ARGS) traded at $6.91 + 1.06 (18.12 percent) on 1,197,403 stock volume.
05/06/16 04:18 PMREMINDER/Media Advisory: Correctional Service of Canada Invites Media to Tour Collins Bay Institution - 28p AVEXIS: Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 09:27p ICAD INC: Submission of Matters to a Vote of Security Holders (form 8-K) 09:27p COMMSCOPE HOLDING COMPANY, INC.: Submission of Matters to a Vote of ...
05/06/16 04:18 PMAveXis (AVXS) Announces Phase 1 Trial Data for AVXS-101 in SMA Type 1 - AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today presented an interim analysis of data as of April 1, 2016 from the ...
05/06/16 02:34 PMAveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - -- Jerry Mendell, MD, Presented Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19 Annual Meeting -- -- Company to Host Webcast Today at 4:30 p.m. Eastern Daylight Time -- CHICAGO, ...
05/06/16 02:11 PMAVEXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -
05/06/16 02:11 PM3:11 pm AveXis presents an interim analysis of data as of April 1 from the ongoing Phase 1 trial of AVXS-101 for the treatment of spinal muscular atrophy Type 1 -
05/05/16 11:40 PMOverseas Shipholding Group Inc Earnings Call scheduled for 4:30 pm ET today -
05/05/16 07:21 AMAveXis to Report First Quarter 2016 Financial Results on Thursday, May 12 - [at noodls] - CHICAGO, May 05, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic ...
04/26/16 06:49 AMAZN Breathes Easy, EXEL Scores FDA Nod, SRPT Disappointed, PETX On The Rise - AZN closed Monday's trading at $30.01, down 0.30%. In after hours, the stock was up 1.63% to $30.50. On May 6, 2016, AveXis Inc. ( AVXS) will present data as of April 1, 2016 from the ongoing phase 1 clinical trial of AVXS-101 in Spinal Muscular Atrophy ...
04/25/16 09:14 AMAveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 - [at noodls] - -- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m. Eastern ...
03/24/16 12:04 PMAVEXIS, INC. Financials -
03/18/16 04:05 PMAVEXIS, INC. Files SEC form 10-K, Annual Report -
03/17/16 05:35 AMEarnings Reported After The Bell Mar.16 - AveXis, Inc. (AVXS) Q4 net loss was $13.2 million compared to net loss of $3.7 million a year ago. Jabil Circuit Inc. (JBL) Q2 profit rose to $78.9 million or $0.41 per share from $52.0 million or $0.27 per share last year. Core earnings for the quarter ...
03/17/16 02:13 AMEdited Transcript of AVXS earnings conference call or presentation 16-Mar-16 8:30pm GMT -
03/16/16 03:30 PMAVEXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/16/16 03:30 PMAveXis Inc Earnings Call scheduled for 4:30 pm ET today -
03/16/16 03:01 PMAveXis Reports Fourth Quarter and Full Year 2015 Financial and Operating Results - [GlobeNewswire] - --Initial public offering raised $98.2 million in net proceeds--. --Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1–. --Conference call March 16 at 4:30 ...
03/16/16 06:07 AMQ4 2015 AveXis, Inc. Earnings Release - After Market Close -
03/16/16 05:36 AMAveXis Inc Earnings Call (Q4 2015) - AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy ...
03/08/16 07:00 AMAveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16 - [GlobeNewswire] - CHICAGO, March 08, 2016-- AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial ...
03/07/16 07:00 AMAveXis Announces Appointments of Daniel G. Welch, Terrence C. Kearney and Frank Verwiel, M.D. to Board of Directors - [GlobeNewswire] - CHICAGO, March 07, 2016-- AveXis, Inc., a leading clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced ...
03/07/16 05:23 AMCoverage initiated on AveXis by Jefferies and Goldman -
02/18/16 08:29 AMOpening Bell, February 18, 2016 -
02/18/16 08:16 AMToday's Bell Ringer, February 18, 2016 -
02/17/16 09:00 AMAveXis, Inc. (Nasdaq:AVXS) to Ring The Nasdaq Stock Market Opening Bell - [GlobeNewswire] - What: AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will visit the Nasdaq MarketSite in ...

Social

About AveXis

AveXis logoAveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AVXS
  • CUSIP:
Key Metrics:
  • Previous Close: $38.19
  • 50 Day Moving Average: $39.75
  • 200 Day Moving Average: $30.87
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $878.87M
  • Current Year EPS Consensus Estimate: $-3.65 EPS
  • Next Year EPS Consensus Estimate: $-3.59 EPS
Additional Links:
AveXis (NASDAQ:AVXS) Chart for Tuesday, July, 26, 2016